BillionToOne (BLLN) Launches Two New Add-ons for Northstar Select

​BillionToOne, Inc. (NASDAQ:BLLN) is one of the Best All-Time Low Stocks to Invest In Now. On February 10, BillionToOne, Inc. (NASDAQ:BLLN) launched two new add-ons to its flagship product, Northstar Select. Northstar Select is a liquid biopsy test, which is recognized as the most sensitive test for spotting therapy-guiding genetic changes in advanced solid tumors. The test has the capability to find 50% more actionable alterations than competitors in a head-to-head study.

​The add-ons include Northstar PGx and Northstar Select CH. The add-ons handle two big hurdles in cancer treatment. Management noted that Northstar PGx checks genes DPYD and UGT1A1 from the same blood draw. These genes affect how patients metabolize common chemotherapy drugs. This is important as some people have poor metabolism, which raises toxicity risks.

egyjanek/Shutterstock.com

On the other hand, Northstar Select CH filters out false positives from clonal hematopoiesis. This is pertinent as when aging white blood cells mutate, they can mimic tumor DNA in blood tests. Northstar Select CH confirms if mutations are truly from the tumor, avoiding ineffective therapies.

​BillionToOne, Inc. (NASDAQ:BLLN) is a precision diagnostics company that uses its proprietary molecular counting platform to detect and measure DNA molecules at the single-molecule level for better disease detection.

While we acknowledge the potential of BLLN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the

.